Cepton Expands With $50 Million Investment From Koito

Cepton Technologies, Inc., a leading provider of state-of-the-art, intelligent, lidar-based solutions, announced today that it has raised over $50 million in Series C funding. This brings Cepton’s total funding to nearly $100 million, providing a strong foundation to substantially ramp up its R&D efforts, expand its footprint in the automotive market and support major customers worldwide. The latest funding round was led by Koito Manufacturing Co., Ltd. (TYO:7276), the automotive Tier 1 and...

Cepton Expands With $50 Million Investment From Koito

Cepton Technologies, Inc., a leading provider of state-of-the-art, intelligent, lidar-based solutions, announced today that it has raised over $50 million in Series C funding. This brings Cepton’s total funding to nearly $100 million, providing a strong foundation to substantially ramp up its R&D efforts, expand its footprint in the automotive market and support major customers worldwide. The latest funding round was led by Koito Manufacturing Co., Ltd. (TYO:7276), the automotive Tier 1 and...

Takeda Demonstrates Ongoing Commitment in Rare Hematology By Continuing to Gather Real-World Evidence and Advance Personalized Treatment

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced that nine hematology abstracts are being presented at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders, EAHAD 2020. The data being presented demonstrate Takeda’s ongoing commitment in rare hematology by continuing to gather important real-world evidence, beyond its product portfolio, and advance personalized treatment for those living with bleeding disorders. Ga...

Takeda Demonstrates Ongoing Commitment in Rare Hematology By Continuing to Gather Real-World Evidence and Advance Personalized Treatment

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced that nine hematology abstracts are being presented at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders, EAHAD 2020. The data being presented demonstrate Takeda’s ongoing commitment in rare hematology by continuing to gather important real-world evidence, beyond its product portfolio, and advance personalized treatment for those living with bleeding disorders. Ga...

Takeda Demonstrates Ongoing Commitment in Rare Hematology By Continuing to Gather Real-World Evidence and Advance Personalized Treatment

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced that nine hematology abstracts are being presented at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders, EAHAD 2020. The data being presented demonstrate Takeda’s ongoing commitment in rare hematology by continuing to gather important real-world evidence, beyond its product portfolio, and advance personalized treatment for those living with bleeding disorders. Ga...

Takeda Demonstrates Ongoing Commitment in Rare Hematology By Continuing to Gather Real-World Evidence and Advance Personalized Treatment

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced that nine hematology abstracts are being presented at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders, EAHAD 2020. The data being presented demonstrate Takeda’s ongoing commitment in rare hematology by continuing to gather important real-world evidence, beyond its product portfolio, and advance personalized treatment for those living with bleeding disorders. Ga...

ABB: Full-Year and Q4 2019 Results

“ABB gave a resilient performance in 2019 in the face of challenging market conditions and a significant transformation. Our revenues and operating margin both improved slightly. The divestment of Power Grids is on track and we are clearly starting to see the positive effects of implementing our new operating model and new culture,” said Peter Voser, Chairman and CEO of ABB. “In line with our dividend policy we are proposing a dividend of 0.80 CHF per share. We are committed to providing a...

ABB: Full-Year and Q4 2019 Results

“ABB gave a resilient performance in 2019 in the face of challenging market conditions and a significant transformation. Our revenues and operating margin both improved slightly. The divestment of Power Grids is on track and we are clearly starting to see the positive effects of implementing our new operating model and new culture,” said Peter Voser, Chairman and CEO of ABB. “In line with our dividend policy we are proposing a dividend of 0.80 CHF per share. We are committed to providing a...

ABB: Full-Year and Q4 2019 Results

“ABB gave a resilient performance in 2019 in the face of challenging market conditions and a significant transformation. Our revenues and operating margin both improved slightly. The divestment of Power Grids is on track and we are clearly starting to see the positive effects of implementing our new operating model and new culture,” said Peter Voser, Chairman and CEO of ABB. “In line with our dividend policy we are proposing a dividend of 0.80 CHF per share. We are committed to providing a...

ABB: Full-Year and Q4 2019 Results

“ABB gave a resilient performance in 2019 in the face of challenging market conditions and a significant transformation. Our revenues and operating margin both improved slightly. The divestment of Power Grids is on track and we are clearly starting to see the positive effects of implementing our new operating model and new culture,” said Peter Voser, Chairman and CEO of ABB. “In line with our dividend policy we are proposing a dividend of 0.80 CHF per share. We are committed to providing a...